Claims
- 1. A pharmaceutical composition product comprising:
a. an aqueous solution formulation of a Y2 receptor binding compound at a concentration sufficient to produce therapeutically effective plasma concentrations and; b. an actuator able to produce an aerosol of said solution, wherein the spray pattern ellipticity ratio of said aerosol is between 1.00 and 1.40 when measured at a height of between 0.5 cm and 10 cm distance from the actuator tip.
- 2. The Y2 receptor binding compound of claim 1 comprising PYY(3-36).
- 3. The aqueous solution of claim 2 wherein said PYY(3-36) is at a concentration of at least 200 ug/mL.
- 4. The product of claim 1 wherein said actuator produces an ellipticity of between 1.00 and 1.30.
- 5. The product of claim 1 comprising an aerosol of between 20 and 200 microliters per actuation.
- 6. The product of claim 3 wherein said ellipticity is between 1.15 and 1.25.
- 7. A pharmaceutical composition product comprising:
a. an aqueous solution of a Y2 receptor binding compound; b. an actuator to produce an aerosol of said solution, wherein the spray pattern major and minor axes of said aerosol are between 10 and 50 mm when measured at a height of between 0.5 cm and 10 cm distance from the actuator tip.
- 8. The Y2 receptor binding compound of claim 6 comprising PYY(3-36).
- 9. The aqueous solution of claim 7 wherein said PYY(3-36) is at a concentration of at least 200 ug/mL.
- 10. The product of claim 7 comprising an aerosol of between 20 and 200 microliters per actuation.
- 11. A pharmaceutical composition product comprising:
a. an aqueous solution formulation of a Y2 receptor binding compound at a concentration sufficient to produce therapeutically effective plasma concentrations and; b. an actuator to produce an aerosol of said solution, wherein less than 10% of the droplets are smaller than 10 microns in size.
- 12. The product of claim 9 wherein less than 5% of the droplets are smaller than 10 microns in size.
- 13. The product of claim 9 wherein less than 1% of the droplets are smaller than 10 microns in size.
- 14. The product of claim 11 comprising an aerosol of between 20 and 200 microliters per actuation.
- 15. A pharmaceutical composition product comprising:
a. an aqueous solution formulation of a Y2 receptor binding compound at a concentration sufficient to produce therapeutically effective plasma concentrations and; b. an actuator selected to produce an aerosol of said solution, wherein droplets between 25 and 700 microns are produced.
- 16. The product of claim 15 comprising an aerosol of between 20 and 200 microliters per actuation.
Priority Claims (1)
Number |
Date |
Country |
Kind |
PCT/US03/40538 |
Dec 2003 |
WO |
|
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This is a continuation application and claims priority under 35 U.S.C. § 120 of co-pending U.S. patent application Ser. No. 10/745,069 filed Dec. 23, 2003, which is a continuation-in-part of U.S. patent application Ser. No. 10/322,266, filed Dec. 17, 2002, and claims priority under 35 U.S.C. § 119 (e) of U.S. Provisional Application No. 60/493,226, filed Aug. 7, 2003, U.S. Provisional Application No. 60/501,170, filed Sep. 8, 2003, U.S. Provisional Application No. 60/510,785, filed Oct. 10, 2003, U.S. Provisional Application No. 60/517,290, filed Nov. 4, 2003; U.S. Provisional Application No. 60/518,812, filed on Nov. 10, 2003; and PCT/US03/40538, filed on Dec. 17, 2003; the entire contents of these applications are incorporated herein by reference.
Provisional Applications (5)
|
Number |
Date |
Country |
|
60493226 |
Aug 2003 |
US |
|
60501170 |
Sep 2003 |
US |
|
60510785 |
Oct 2003 |
US |
|
60517290 |
Nov 2003 |
US |
|
60518812 |
Nov 2003 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
10745069 |
Dec 2003 |
US |
Child |
10780325 |
Feb 2004 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
10322266 |
Dec 2002 |
US |
Child |
10745069 |
Dec 2003 |
US |